Delaying surgery with chemotherapy for osteosarcoma of the extremities

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 6, 2004, Pages 1243-1256

  Bielack, Stefan S ^a   Machatschek, Jan Nicolas ^a   Flege, Silke ^a   Jürgens, Heribert ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Chemotherapy; Limb Salvage; Neoadjuvant; Osteosarcoma

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE; AZACITIDINE; BLEOMYCIN; CARBOPLATIN; CARBOXYPEPTIDASE G2; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLIC ACID DERIVATIVE; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERLEUKIN 1ALPHA; IPROPLATIN; LEXIDRONAM SAMARIUM SM 153; LIPOSOME; METHOTREXATE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PACLITAXEL; TOPOTECAN; TRABECTEDIN; TRASTUZUMAB;

ACUTE KIDNEY FAILURE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; DEATH; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; FANCONI RENOTUBULAR SYNDROME; HUMAN; INFERTILITY; KIDNEY TUBULE DISORDER; LIMB; METASTASIS; MULTIMODALITY CANCER THERAPY; NEPHROTOXICITY; NEUROTOXICITY; OSTEOSARCOMA; OTOTOXICITY; PREOPERATIVE TREATMENT; PROGNOSIS; REVIEW; SKIN TOXICITY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CLINICAL TRIALS; EXTREMITIES; HUMANS; NEOADJUVANT THERAPY; OSTEOSARCOMA; TREATMENT OUTCOME;

EID: 3042813613     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.6.1243     Document Type: Review

References (137)

1. HUVOS A: Bone tumors. Diagnosis, treatment, and prognosis. WB Saunders Company, Philadelphia, PA, USA (1991).
2. ARNDT CA, CRIST WM: Common musculoskeletal tumors of childhood and adolescence. N. Engl. J. Med. (1999) 341(5):342-352.
3. FLETCHER CDM, UNNI KK, MERTENS F: WHO Classification of tumours. Pathology and genetics of tumours of soft tissue and bone. IARC Press, Lyon, France (2002).
4. OKADA K, FRASSICA FJ, SIM FH, BEABOUT JW, BOND JR, UNNI KK: Parosteal osteosarcoma. A clinicopathological study. J. Bone Joint Surg. Am. (1994) 76(3):366-378.
5. SHETH DS, YASKO AW, RAYMOND AK et al.: Conventional and dedifferentiated parosteal osteosarcoma. Diagnosis, treatment, and outcome. Cancer (1996) 78(10):2136-2145.
6. SCHAJOWICZ F, MCGUIRE MH, SANTINI AE, MUSCOLO DL, GITELIS S: Osteosarcomas arising on the surfaces of long bones. J. Bone Joint Surg. Am. (1988) 70(4):555-564.
7. RAYMOND AK: Surface osteosarcoma. Clin. Orthop. (1991) (270):140-148.
8. OKADA K, UNNI KK, SWEE RG, SIM FH: High grade surface osteosarcoma: a clinicopathologic study of 46 cases. Cancer (1999) 85(5):1044-1054.
9. KURT AM, UNNI KK, MCLEOD RA, PRITCHARD DJ: Low-grade intraosseous osteosarcoma. Cancer (1990) 65(6):1418-1428.
10. CHOONG PF, PRITCHARD DJ, ROCK MG, SIM FH, MCLEOD RA, UNNI KK: Low grade central osteogenic sarcoma. A long-term followup of 20 patients. Clin. Orthop. (1996) 322:198-206.
11. BERTONI F, BACCHINI P, FABBRI N et al.: Osteosarcoma. Low-grade intraosseous-type osteosarcoma, histologically resembling parosteal osteosarcoma, fibrous dysplasia, and desmoplastic fibroma. Cancer (1993) 71(2):338-345.
12. SMEELE LE, KOSTENSE PJ, VAN DER WAAL I, SNOW GB: Effect of chemotherapy on survival of craniofacial osteosarcoma: a systematic review of 201 patients. J. Clin. Oncol. (1997) 15(1):363-367.
13. STILLER CA, CRAFT AW, CORAZZIARI I: Survival of children with bone sarcoma in Europe since 1978: results from the EUROCARE study. Eur. J. Cancer (2001) 37(6):760-766.
14. KAATSCH P, SPIX C MICHAELIS M: Jahresbericht 1999. Deutsches Kinderkrebsregister. Mainz, Johannes-Gutenberg-Universität Institut für Medizinische Statistik und Information. Report (2000).
15. HAWKINS MM, WILSON LM, BURTON HS et al.: Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J. Natl. Cancer Inst. (1996) 88(5):270-278.
16. TUCKER MA, D'ANGIO GJ, BOICE JD Jr et al.: Bone sarcomas linked to radiotherapy and chemotherapy in children. N. Engl. J. Med. (1987) 317(10):588-593.
17. KUTTESCH JF Jr, WEXLER LH, MARCUS RB et al.: Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J. Clin. Oncol. (1996) 14(10):2818-2825.
18. LINK MP, GOORIN AM, MISER AW et al.: The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N. Engl. J. Med. (1986) 314(25):1600-1606.
19. EILBER F, GIULIANO A, ECKARDT J, PATTERSON K, MOSELEY S, GOODNIGHT J: Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J. Clin. Oncol. (1987) 5(1):21-26.
20. MARCOVE RC, MIKE V, HAJEK JV, LEVIN AG, HUTTER RV: Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases. J. Bone Joint Surg. Am. (1970) 52(3):411-423.
21. BIELACK SS, KEMPF-BIELACK B, DELLING G et al.: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J. Clin. Oncol. (2002) 20(3):776-790.
22. ENNEKING WF, SPANIER SS, GOODMAN MA: A system for the surgical staging of musculoskeletal sarcoma. Clin. Orthop. (1980) 153:106-120.
23. PICCI P, SANGIORGI L, ROUGRAFF BT, NEFF JR, CASADEI R, CAMPANACCI M: Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J. Clin. Oncol. (1994) 12(12):2699-2705.
24. HOSALKAR HS, DORMANS JP: Limb sparing surgery for pediatric musculoskeletal tumors. Pediatr. Blood Cancer (2004) 42(4):295-310.
25. RAO BN, RODRIGUEZ-GALINDO C: Local control in childhood extremity sarcomas: salvaging limbs and sparing function. Med. Pediatr. Oncol. (2003) 41(6):584-587.
26. KAGER L, ZOUBEK A, POTSCHGER U et al.: Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J. Clin. Oncol. (2003) 21(10):2011-2018.
27. BIELACK SS, KEMPF-BIELACK B, WINKLER K: Osteosarcoma: relationship of response to preoperative chemotherapy and type of surgery to local recurrence. J. Clin. Oncol. (1996) 14(2):683-684.
28. JAFFE N, CARRASCO H, RAYMOND K, AYALA A, EFTEKHARI F: Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer (2002) 95(10):2202-2210.
29. WEITMAN S, OCHOA S, SULLIVAN J et al.: Pediatric Phase II cancer chemotherapy trials: a Pediatric Oncology Group study. J. Pediatr. Hematol. Oncol. (1997) 19(3):187-191.
30. JAFFE N: Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer (1972) 30(6):1627-1631.
31. JAFFE N, PAED D, FARBER S et al.: Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Cancer (1973) 31(6):1367-1373.
32. DJERASSI I: Letter: Methotrexate-citrovorum factor in treating osteogenic sarcoma. N. Engl. J. Med. (1975) 292(21):1133-1134.
33. ACKLAND SP, SCHILSKY RL: High-dose methotrexate: a critical reappraisal. J. Clin. Oncol. (1987) 5(12):2017-2031.
34. BLEYER WA: Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat. Rev. (1977) 4(2):87-101.
35. JACOBS SA, STOLLER RG, CHABNER BA, JOHNS DG: 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J. Clin. Invest. (1976) 57(2):534-538.
36. WIDEMANN BC, BALIS FM, KEMPF-BIELACK B et al.: High-dose methotrexate-induced nephrotoxicity: incidence in osteosarcoma. Patients, treatment and outcome. Cancer (2004) 100:2222-2232.
37. FLOMBAUM CD, MEYERS PA: High-dose leucovorin as sole therapy for methotrexate toxicity. J. Clin. Oncol. (1999) 17(5):1589-1594.
38. WANG JJ, CORTES E, SINKS LF, HOLLAND JF: Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease. Cancer (1971) 28(4):837-843.
39. CORTES EP, HOLLAND JF, WANG JJ, SINKS LF: Doxorubicin in disseminated osteosarcoma. JAMA (1972) 10(221):1132-1138.
40. GOTTLIEB JA, BAKER LH, QUAGLIANA JM et al.: Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide. Cancer (1972) 30(6):1632-1638.
41. ROSEN G, NIRENBERG A, CAPARROS B et al.: Osteogenic sarcoma: eighty-percent, three-year disease-free survival with combination chemotherapy (T-7). Natl. Cancer Inst. Monogr. (1981) 56:213-220.
42. ROSEN G, CAPARROS B, HUVOS AG et al.: Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer (1982) 49(6):1221-1230.
43. WINKLER K, BERON G, KOTZ R et al.: Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J. Clin. Oncol. (1984) 2(6):617-624.
44. WINKLER K, BERON G, DELLING G et al.: Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J. Clin. Oncol. (1988) 6(2):329-337.
45. BACCI G, PICCI P, RUGGIERI P et al.: Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer (1990) 65(11):2539-2553.
46. SAETER G, ALVEGARD TA, ELOMAA I, STENWIG AE, HOLMSTROM T, SOLHEIM OP: Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J. Clin. Oncol. (1991) 9(10):1766-1775.
47. BRAMWELL VH, BURGERS M, SNEATH R et al.: A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J. Clin. Oncol. (1992) 10(10):1579-1591.
48. MEYERS PA, HELLER G, HEALEY J et al.: Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J. Clin. Oncol. (1992) 10(1):5-15.
49. SOUHAMI RL, CRAFT AW, VAN DER EIJKEN JW et al.: Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet (1997) 350(9082):911-917.
50. PROVISOR AJ, ETTINGER LJ, NACHMAN JB et al.: Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J. Clin. Oncol. (1997) 15(1):76-84.
51. FUCHS N, BIELACK SS, EPLER D et al.: Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann. Oncol. (1998) 9(8):893-899.
52. MEYERS PA, GORLICK R, HELLER G et al.: Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin. Oncol. (1998) 16(7):2452-2458.
53. BACCI G, RUGGIERI P, BERTONI F et al.: Local and systemic control for osteosarcoma of the extremity treated with neoadjuvant chemotherapy and limb salvage surgery: the Rizzoli experience. Oncol. Rep. (2000) 7(5):1129-1133.
54. BACCI G, BRICCOLI A, FERRARI S et al.: Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur. J. Cancer (2001) 37(16):2030-2039.
55. MEYER WH, PRATT CB, POQUETTE CA et al.: Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. J. Clin. Oncol. (2001) 19(1):171-182.
56. MEYERS PA, SCHWARTZ CL, AND BERNSTEIN M: Addition of ifosfamide and muramyl tripeptide to cisplatin, doxorubicin and high-dose methotrexate improves event-free survival (EFS) in localized osteosarcoma (OS). Proceedings of the American Society of Clinical Oncology (2001) 20:1463 (Abstract).
57. BACCI G, FERRARI S, LONGHI A et al.: High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J. Chemother. (2002) 14(2):198-206.
58. LEWIS I, NOOIJ M, WHELAN JS et al.: Chemotherapy at standard or increased dose intensity in patients with operable osteosarcoma of the extremity: a randomized controlled trial of the European Osteosarcoma Intergroup (ISRCTN 86294690). Society of Pediatric Oncology Meeting (2003) (Abstract).
59. GOORIN AM, SCHWARTZENTRUBER DJ, DEVIDAS M et al.: Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J. Clin. Oncol. (2003) 21(8):1574-1580.
60. SMELAND S, MULLER C, ALVEGARD TA et al.: Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur. J. Cancer (2003) 39(4):488-494.
61. OCHS JJ, FREEMAN AI, DOUGLASS HO Jr, HIGBY DS, MINDELL ER, SINKS LF: Cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat. Rep. (1978) 62(2):239-245.
62. BAUM ES, GAYNON P, GREENBERG L, KRIVIT W, HAMMOND D: Phase II trail cisplatin in refractory childhood cancer: Children's Cancer Study Group Report. Cancer Treat. Rep. (1981) 65(9-10):815-822.
63. WINKLER K, BIELACK S, DELLING G et al.: Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86). Cancer (1990) 66(8):1703-1710.
64. MARTI C, KRONER T, REMAGEN W, BERCHTOLD W, CSERHATI M, VARINI M: High-dose ifosfamide in advanced osteosarcoma. Cancer Treat. Rep. (1985) 69(1):115-117.
65. HARRIS MB, CANTOR AB, GOORIN AM et al.: Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med. Pediatr. Oncol. (1995) 24(2):87-92.
66. PRATT CB, DOUGLASS EC ETCUBANAS E et al.: Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988. Semin. Oncol. (1989) 16(1 Suppl. 3):51-55.
67. GASPARINI M: High-dose ifosfamide alone and in combination for solid malignancies in childhood. Cancer Chemother. Pharmacol. (1986) 18(Suppl. 2)S18.
68. GENTET JC, BRUNAT-MENTIGNY M, DE-MAILLE MC et al.: Ifosfamide and etoposide in childhood osteosarcoma. A Phase II study of the French Society of Paediatric Oncology. Eur. J. Cancer (1997) 33(2):232-237.
69. GOORIN AM, HARRIS MB, BERNSTEIN M et al.: Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J. Clin. Oncol. (2002) 20(2):426-433.
70. ROSSI R. Nephrotoxicity of ifosfamide-moving towards understanding the molecular mechanisms Nephrol. Dial. Transplant. (1997) 12(6):1091-1092.
71. PETRILLI AS, KECHICHIAN R, BRONISCER A et al.: Activity of intraarterial carboplatin as a single agent in the treatment of newly diagnosed extremity osteosarcoma. Med. Pediatr. Oncol. (1999) 33(2):71-75.
72. FERGUSON WS, HARRIS MB, GOORIN AM et al.: Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial. J. Pediatr. Hematol. Oncol. (2001) 23(6):340-348.
73. ETTINGER LJ, GAYNON PS, KRAILO MD et al.: A Phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group. Cancer (1994) 73(4):1297-1301.
74. KEBUDI R, GORGUN O, AYAN I: Oral etoposide for recurrent/progressive sarcomas of childhood. Pediatr. Blood Cancer (2004) 42(4):320-324.
75. SALEH RA, GRAHAM-POLE J, CASSANO W et al.: Response of osteogenic sarcoma to the combination of etoposide and cyclophosphamide as neoadjuvant chemotherapy. Cancer (1990) 65(4):861-865.
76. RODRIGUEZ-GALINDO C, DAW NC, KASTE SC et al.: Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. J. Pediatr. Hematol. Oncol. (2002) 24(4):250-255.
77. SRINIVASAN U, REAMAN GH, POPLACK DG, GLAUBIGER DL, LEVINE AS: Phase II study of 5-azacytidine in sarcomas of bone. Am. J. Clin. Oncol. (1982) 5(4):411-415.
78. TAN C ETCUBANAS E, WOLLNER N et al.: Adriamycin-an antitumor antibiotic in the treatment of neoplastic diseases. Cancer (1973) 32(1):9-17.
79. PRATT CB, MEYER WH, HOWLETT N et al.: Phase II study of 5-fluorouracil/leucovorin for pediatric patients with malignant solid tumors. Cancer (1994) 74(9):2593-2598.
80. PATEL SR, PAPADOPOULOS NE, PLAGER C et al.: Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants. Cancer (1996) 78(4):741-744.
81. GIAN VG, JOHNSON TJ, MARSH RW, SCHUHMACHER C, LYNCH JW: A Phase II trial of paclitaxel in the treatment of recurrent or metastatic soft tissue sarcomas or bone sarcomas. J. Exp. Ther. Oncol. (1996) 1(3):186-190.
82. BLANEY SM, SEIBEL NL, O'BRIEN M et al.: Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. J. Clin. Oncol. (1997) 15(4):1538-1543.
83. SEIBEL NL, BLANEY SM, O'BRIEN M et al.: Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. Clin. Cancer Res. (1999) 5(4):733-737.
84. NITSCHKE R, PRATT C, HARRIS M et al.: Evaluation of CHIP (iproplatin) in recurrent pediatric malignant solid tumors. A Phase II study (Pediatric Oncology Group). Invest. New Drugs (1992) 10(2):93-96.
85. PAWINSKI A, CROWTHER D, KEIZER HJ et al.: The EORTC Phase II study of iproplatin in advanced osteogenic sarcoma. Eur. J. Cancer (1999) 35(1):163-164.
86. LAVERDIERE C, KOLB EA, SUPKO JG et al.: Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer (2003) 98(4):832-840.
87. BLANEY SM, NEEDLE MN, GILLESPIE A et al.: Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin. Cancer Res. (1998) 4(2):357-360.
88. MERIMSKY O, MELLER I, FLUSSER G et al.: Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a Phase II study. Cancer Chemother. Pharmacol. (2000) 45(2):177-181.
89. COLOMBAT P, BIRON P, COZE C et al.: Failure of high-dose alkylating agents in osteosarcoma. Solid Tumors Working Party. Bone Marrow Transplant. (1994) 14(4):665-666.
90. SAUERBREY A, BIELACK S, KEMPF-BIELACK B, ZOUBEK A, PAULUSSEN M, ZINTL F: High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma. Bone Marrow Transplant. (2001) 27(9):933-937.
91. FAGIOLI F, AGLIETTA M, TIENGHI A et al.: High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study J. Clin. Oncol (2002) 20(8):2150-2156.
92. BRULAND OS, SKRETTING A, SOLHEIM OP, AAS M: Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach. Acta Oncol. (1996) 35(3):381-384.
93. FRANZIUS C, SCHUCK A, BIELACK SS: High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases J. Clin. Oncol. (2002) 20(7):1953-1954.
94. ANDERSON PM, WISEMAN GA, DISPENZIERI A et al.: High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J. Clin. Oncol. (2002) 20(1):189-196.
95. FRANZIUS C, BIELACK S, FLEGE S et al.: High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma. Nuklearmedizin (2001) 40(6):215-220.
96. ANDERSON PM, WISEMAN GA, DISPENZIERI A et al.: High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J. Clin. Oncol. (2002) 20(1):189-196.
97. FRANZIUS C, BIELACK S, FLEGE S et al.: High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma. Nuklearmedizin (2001) 40:215-220.
98. FRANZIUS C, SCHUCK A, BIELACK S: High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J. Clin. Oncol. (2002) 20:1953-1954.
99. KLEINERMAN ES, RAYMOND AK, BUCANA CD et al.: Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol. Immunother. (1992) 34(4):211-220.
100. MACEWEN EG, KURZMAN ID, ROSENTHAL RC et al.: Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J. Natl. Cancer Inst. (1989) 81(12):935-938.
101. KLEINERMAN ES, GANO JB, JOHNSTON DA, BENJAMIN RS, JAFFE N: Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am. J. Clin. Oncol. (1995) 18(2):93-99.
102. STRANDER H, EINHORN S: Effect of human leukocyte interferon on the growth of human osteosarcoma cells in tissue culture. Int. J. Cancer (1977) 19(4):468-473.
103. BROSJO O, BAUER HC, BROSTROM LA, NILSSON OS, REINHOLT FP, TRIBUKAIT B: Growth inhibition of human osteosarcomas in nude mice by human interferon-alpha: significance of dose and tumor differentiation. Cancer Res. (1987) 47(1):258-262.
104. BROSJO O, BAUER HC, BROSTROM LA et al.: Influence of human alpha-interferon on four human osteosarcoma xenografts in nude mice. Cancer Res. (1985) 45(11 Pt 2):5598-5602.
105. EDMONSON JH, LONG HJ, FRYTAK S, SMITHSON WA, ITRI LM: Phase II study of recombinant alfa-2a interferon in patients with advanced bone sarcomas. Cancer Treat. Rep. (1987) 71(7-8):747-748.
106. STRANDER H, BAUER HC, BROSJO O et al.: Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncol. (1995) 34(6):877-880.
107. WORTH LL, JAFFE N, BENJAMIN RS et al.: Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma. Clin. Cancer Res. (1997) 3(10):1721-1729.
108. GORLICK R, HUVOS AG, HELLER G et al.: Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J. Clin. Oncol. (1999) 17(9):2781-2788.
109. THOMAS DG, GIORDANO TJ, SANDERS D, BIERMANN JS, BAKER L: Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin. Cancer Res. (2002) 8(3):788-793.
110. TAYLOR WF, IVINS JC, DAHLIN DC, EDMONSON JH, PRITCHARD DJ: Trends and variability in survival from osteosarcoma. Mayo Clin. Proc. (1978) 53(11):695-700.
111. CARTER SK: Adjuvant chemotherapy in osteogenic sarcoma: the triumph that isn't? J. Clin. Oncol. (1984) 2(3):147-148.
112. DAHLIN DC: Problems in the interpretation of results of treatment for osteosarcoma. Mayo Clin. Proc. (1979) 54(9):621-622.
113. TAYLOR WF, IVINS JC, PRITCHARD DJ, DAHLIN DC, GILCHRIST GS, EDMONSON JH: Trends and variability in survival among patients with osteosarcoma: a 7-year update. Mayo Clin. Proc. (1985) 60(2):91-104.
114. LINK MP, GOORIN AM, HOROWITZ M et al.: Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin. Orthop. (1991)(270):8-14.
115. EILBER F, GIULIANO A, ECKARDT J, PATTERSON K, MOSELEY S, GOODNIGHT J: Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J. Clin. Oncol. (1987) 5(1):21-26.
116. SMITH MA, UNGERLEIDER RS, HOROWITZ ME, SIMON R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J. Natl. Cancer Inst. (1991) 83(20):1460-1470.
117. WEXLER LH: Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane. Semin. Oncol (1998) 25(4 Suppl. 10):86-92.
118. BIELACK SS, ERTTMANN R, KEMPF-BIELACK B, WINKLER K: Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur. J. Cancer (1996) 32A(10):1652-1660.
119. PRATT CB, HOWARTH C, RANSOM JL et al.: High-dose methotrexate used alone and in combination for measurable primary or metastatic osteosarcoma. Cancer Treat. Rep. (1980) 64(1):11-20.
120. DELEPINE N, DELEPINE G, DESBOIS JC. A monocentric therapy study: an approach to optimize the results of the treatment of osteosarcoma by protocols based upon HDMTX, associated with systematic conservative surgery. Cancer Treat. Res. (1993) 62 327-332.
121. BACCI G, FERRARI S, DELEPINE N et al.: Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J. Clin. Oncol. (1998) 16(2):658-663.
122. GRAF N, WINKLER K, BETLEMOVIC M, FUCHS N, BODE U: Methotrexate pharmacokinetics and prognosis in osteosarcoma J. Clin. Oncol. (1994) 12(7):1443-1451.
123. AQUERRETA I, ALDAZ A, GIRALDEZ J, SIERRASESUMAGA L: Methotrexate pharmacokinetics and survival in osteosarcoma. Pediatr. Blood Cancer (2004) 42(1):52-58.
124. DELEPINE N, DELEPINE G, BACCI G, ROSEN G, DESBOIS JC: Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature. Cancer (1996) 78(10):2127-2135.
125. BIELACK SS, BERON G, WINKLER K: Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma: analysis of the literature. Cancer (1997) 80(3):516-518.
126. MOSENDE C, GUTIERREZ M, CAPARROS B, ROSEN G: Combination chemotherapy with bleomycin, cyclophosphamide and dactinomycin for the treatment of osteogenic sarcoma. Cancer (1977) 40(6):2779-2786.
127. PRATT CB, EPELMAN S, JAFFE N: Bleomycin, cyclophosphamide, and dactinomycin in metastatic osteosarcoma: lack of tumor regression in previously treated patients. Cancer Treat. Rep. (1987) 71(4):421-423.
128. ROSEN G, MURPHY ML, HUVOS AG, GUTIERREZ M, MARCOVE RC: Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer (1976) 37(1):1-11.
129. ROSEN G, MARCOVE RC, CAPARROS B, NIRENBERG A, KOSLOFF C, HUVOS AG: Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer (1979) 43(6):2163-2177.
130. SALZER-KUNTSCHIK M, BRAND G, DELLING G: [Determination of the degree of morphological regression following chemotherapy in malignant bone tumors]. Pathologe (1983) 4(3):135-141.
131. DAVIS AM, BELL RS, GOODWIN PJ: Prognostic factors in osteosarcoma: a critical review. J. Clin. Oncol. (1994) 12(2):423-431.
132. BACCI G, BRICCOLI A, ROCCA M et al.: Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann. Oncol. (2003) 14(7):1126-1134.
133. WEEDEN S, GRIMER RJ, CANNON SR, TAMINIAU AH, USCINSKA BM: The effect of local recurrence on survival in resected osteosarcoma. Eur. J. Cancer (2001) 37(1):39-46.
134. FLETCHER BD, HANNA SL: Musculoskeletal neoplasms: dynamic Gd-DTPA-enhanced MR imaging. Radiology (1990) 177(1):287-288.
135. KNOP J, DELLING G, HEISE U, WINKLER K: Scintigraphic evaluation of tumor regression during preoperative chemotherapy of osteosarcoma. Correlation of 99mTc-methylene diphosphonate parametric imaging with surgical histopathology. Skeletal Radiol. (1990) 19(3):165-172.
136. FRANZIUS C, BIELACK S, FLEGE S, SCIUK J, JURGENS H, SCHOBER O: Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. J. Nucl. Med. (2002) 43(8):1012-1017.
137. SCHULTE M, BRECHT-KRAUSS D, WERNER M et al.: Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J. Nucl. Med. (1999) 40(10):1637-1643.